Antibody dynamics and viral load in COVID-19: differences in mild, moderate and severe cases

References

• Liu Y, Liao W, Wan L, et al. Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19. Viral Immunol. 2021;34(5):1–12. doi: 10.1089/vim.2020.0062.
   PubMed Web of Science ®Google Scholar
• Waller H, Carmona-Vicente N, James A, et al. Viral load at hospitalization is an independent predictor of severe COVID-19. Eur J Clin Invest. 2023;53:e13882.
   PubMed Web of Science ®Google Scholar
• Pawar RD, Balaji L, Mehta S, et al. Viral load and disease severity in COVID-19. Intern Emerg Med. 2022;17(2):359–367. doi: 10.1007/s11739-021-02786-w.
   PubMed Web of Science ®Google Scholar
• Long H, Zhao J, Zeng HL, et al. Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study. BMC Infect Dis. 2021;21(1):1282. doi: 10.1186/s12879-021-07002-w.
   PubMed Web of Science ®Google Scholar
• Kong WH, Zhao R, Zhou JB, et al. Serologic response to SARS-CoV-2 in COVID-19 patients with different severity. Virol Sin. 2020;35(6):752–757. doi: 10.1007/s12250-020-00270-x.
   PubMed Web of Science ®Google Scholar
• Cheng ML, Liu HY, Zhao H, et al. Longitudinal dynamics of antibody responses in recovered COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):137. doi: 10.1038/s41392-021-00559-7.
   PubMed Web of Science ®Google Scholar
• Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, et al. Antibody responses in COVID-19: a review. Front Immunol. 2021;12:633184. doi: 10.3389/fimmu.2021.633184.
   PubMedGoogle Scholar
• Efrati S, Catalogna M, Hamed RA, et al. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients. Sci Rep. 2021;11(1):13780. doi: 10.1038/s41598-021-93175-y.
   PubMed Web of Science ®Google Scholar
• Borremans B, Gamble A, Orager KC, et al. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. eLife. 2020;9:e60122. doi: 10.7554/eLife.60122.
   PubMed Web of Science ®Google Scholar
• Sánchez-Zuno GA, Matuz-Flores MG, González-Estevez G, et al. A review: antibody-dependent enhancement in COVID-19: the not so friendly side of antibodies. Int J Immunopathol Pharmacol. 2021;35:20587384211050199. doi: 10.1177/20587384211050199.
   Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880. doi: 10.1016/j.cell.2021.01.007.
   PubMed Web of Science ®Google Scholar
• Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146(1):211–213.e4. doi: 10.1016/j.jaci.2020.04.013.
   PubMed Web of Science ®Google Scholar
• WHO. Clinical management of COVID-19: living guideline. Geneva: World Health Organization; 2022. https://apps.who.int/iris/handle/10665/362783
   Google Scholar
• Boechat JL, Chora I, Morais A, et al. The immune response to SARS-CoV-2 and COVID-19 immunopathology – current perspectives. Pulmonology. 2021;27(5):423–437. doi: 10.1016/j.pulmoe.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–644. doi: 10.1038/s41586-021-03207-w.
   PubMed Web of Science ®Google Scholar
• Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One. 2020;15(10):e0240502. doi: 10.1371/journal.pone.0240502.
   PubMed Web of Science ®Google Scholar
• Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12(1):1813. doi: 10.1038/s41467-021-22034-1.
   PubMed Web of Science ®Google Scholar
• Patil HP, Rane PS, Shrivastava S, et al. Antibody (IgA, IgG, and IgG subtype) responses to SARS-CoV-2 in severe and nonsevere COVID-19 patients. Viral Immunol. 2021;34(3):201–209. doi: 10.1089/vim.2020.0321.
   PubMed Web of Science ®Google Scholar
• Yan X, Chen G, Jin Z, et al. Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. J Med Virol. 2022;94(1):380–383. doi: 10.1002/jmv.27274.
   PubMed Web of Science ®Google Scholar
• Dobaño C, Ramírez-Morros A, Alonso S, et al. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Med. 2021;19(1):155. doi: 10.1186/s12916-021-02032-2.
   PubMed Web of Science ®Google Scholar
• Feng C, Shi J, Fan Q, et al. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nat Commun. 2021;12(1):4984. doi: 10.1038/s41467-021-25312-0.
   PubMed Web of Science ®Google Scholar
• Farshadpour F, Taherkhani R. Antibody-dependent enhancement and the critical pattern of COVID-19: possibilities and considerations. Med Princ Pract. 2021;30(5):422–429. doi: 10.1159/000516693.
   PubMed Web of Science ®Google Scholar
• Ameratunga R, Woon ST, Lea E, et al. The (apparent) antibody paradox in COVID-19. Expert Rev Clin Immunol. 2022;18(4):335–345. doi: 10.1080/1744666X.2022.2044797.
   PubMed Web of Science ®Google Scholar
• Duarte LF, Gálvez NM, Iturriaga C, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021;12:742914. doi: 10.3389/fimmu.2021.742914.
   PubMed Web of Science ®Google Scholar
• Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014. doi: 10.1126/sciimmunol.abn8014.
   PubMed Web of Science ®Google Scholar
• Anantharaj A, Gujjar S, Verma N, et al. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2022;146:105060. doi: 10.1016/j.jcv.2021.105060.
   PubMed Web of Science ®Google Scholar
• Challenger JD, Foo CY, Wu Y, et al. Modelling upper respiratory viral load dynamics of SARS-CoV-2. BMC Med. 2022;20(1):25. doi: 10.1186/s12916-021-02220-0.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–657. doi: 10.1016/S1473-3099(20)30232-2.
   PubMed Web of Science ®Google Scholar
• Fontana LM, Villamagna AH, Sikka MK, et al. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature. Infect Control Hosp Epidemiol. 2021;42(6):659–668. doi: 10.1017/ice.2020.1273.
   PubMed Web of Science ®Google Scholar
• Caplan A, Bates KW, Brioni C, et al. Clinical characteristics and viral load dynamics of COVID-19 in a mildly or moderately symptomatic outpatient sample. PLoS One. 2021;16(10):e0258970. doi: 10.1371/journal.pone.0258970.
   PubMed Web of Science ®Google Scholar
• Dadras O, Afsahi AM, Pashaei Z, et al. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. 2022;10:e580.
   PubMed Web of Science ®Google Scholar
• Mehraeen E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19: a systematic review. Eur J Integr Med. 2020;40:101226. doi: 10.1016/j.eujim.2020.101226.
   PubMed Web of Science ®Google Scholar